Illumina Acquires Advanced Liquid Logic, Leader in Digital Microfluidics Solutions

  Illumina Acquires Advanced Liquid Logic, Leader in Digital Microfluidics

 Acquisition a Key Component in the Development of Complete Sample-to-Answer
                   Solutions for Next-Generation Sequencing

Business Wire

SAN DIEGO -- July 23, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Advanced
Liquid Logic (ALL), a leading provider of liquid handling solutions. ALL, now
a wholly owned subsidiary of Illumina, has developed a proprietary “digital
microfluidics” technology based on electrowetting that precisely manipulates
small droplets within a sealed disposable cartridge to perform complex
laboratory protocols. This proven technology will enable Illumina to deliver
the simplest and most efficient sample-to-answer next-generation sequencing
(NGS) workflow.

“For our research customers, ALL’s technology will further streamline the
industry's simplest NGS workflow, while for clinical and applied markets,
where ease of use and consistency are especially valued, it will allow us to
offer integrated, end-to-end solutions,” said Christian Henry, Senior Vice
President and General Manager of Illumina’s Genomic Solutions business. “ALL
brings an impressive IP portfolio in digital microfluidics and a talented team
with a track record of innovation.”

One of Illumina's goals is to provide customers with a holistic set of tools
to go from biological sample to answer quickly and easily, minimizing the risk
of errors and reducing hands-on time in the lab. To that end, Illumina
recently announced it is collaborating with leading vendors of liquid handling
robotic platforms to make automation solutions for high-throughput sample
preparation more accessible. With its acquisition of ALL, Illumina will be
able to introduce similar benefits to its low- and mid-throughput customers.

ALL’s versatile technology has been demonstrated across numerous applications,
including nucleic acid isolation from various sample types and library
generation for next-generation sequencing. Its robust solution has a clear
advantage in precisely handling low sample volumes, which is an increasingly
important focus for customers.

For more information about ALL’s technology, visit

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this


Illumina, Inc.
Rebecca Chambers
Jennifer Temple
Press spacebar to pause and continue. Press esc to stop.